Combination of luminescence homogeneous assay technology with a high capacity HTS plate reader offers excellent results, versatility and ease-of-use with high sensitivity
PerkinElmer Life and Analytical Sciences, a provider of drug discovery, life science research, and analytical solutions, has announced that its flagship EnVision plate reader now provides superior AlphaScreen technology.
The combination of luminescence homogeneous assay technology with a high capacity HTS plate reader offers excellent results, versatility and ease-of-use with high sensitivity and a wide, dynamic range.
EnVision is a high-performance detection solution for all major application areas including reporter gene assays, enzyme assays, receptor ligand binding assays, cellular assays, genotyping assays and future assay types.
Modular and flexible, it gives users the ability to pick and choose only the application modules they require.
AlphaScreen technology is a highly sensitive, non-radioactive homogeneous assay technology that allows the screening of a large range of biological interactions and activities.
"Both the EnVision plate reader and AlphaScreen technology are leading solutions in today's drug discovery market," said Deb Brusini, business director, screening and research, PerkinElmer Life and Analytical Sciences. "Combining these strong products provides superior advantage for laboratories seeking to meet the increasing demand for higher throughput and lower reagent volumes."
